## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

October 18, 2007

**Date of Report (date of earliest event reported)** 

HEMOSENSE, INC.

(Exact name of Registrant as specified in its charter)

**Delaware** (State or other jurisdiction of

001-32541 (Commission File Number) 77-0452938 (I.R.S. Employer

**Identification Number)** 

incorporation or organization)

651 River Oaks Parkway

San Jose, California 95134

(Address of principal executive offices)

(408) 719-1393

(Registrant s telephone number, including area code)

1

#### N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01 Other Events.

On October 18, 2007, HemoSense issued press release announcing that Beckman Coulter, Inc. (Beckman) has filed a complaint in the United States District Court for the Northern District of California, alleging that HemoSense is infringing a patent held by Beckman. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

Exhibit No. Description

99.1 Press release dated October 18, 2007.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

#### HEMOSENSE, INC.

Date: October 22, 2007

By: /s/ James D. Merselis

James D. Merselis

President and Chief Executive Officer

#### EXHIBIT INDEX

**Exhibit No. Description** 99.1 Press release dated October 18, 2007.